Latest news
Debiopharm and Ascenta Therapeutics, Inc. announce an exclusive license agreement for the development and commercialization of the IAP (Inhibitor of…
Debiopharm Group™ s’installe dans son “Espace «après-demain»” au sein du quartier de l’innovation de l’EPFL
Debiopharm and Yale announce an exclusive license agreement for the development and commercialization of Debio 1036, a first-in-class inhibitor for…
The Debiopharm Group and Marina Biotech Partner to Develop and Commercialise RNAi-based Therapies for the Treatment of Bladder Cancer
Diagnoplex Closes an Extension of Its Series A Financing with a substantial Investment by Debiopharm Group™
Frost & Sullivan Presents Debiopharm Group™ with “European Biopharmaceuticals Company of the Year Award”
Abionic wins the ‘Prix Debiopharm Valais pour les Sciences de la Vie’ for its innovative biomedical device for diagnostic testing
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.